An international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetes

Current Medical Research and Opinion

Volumn 18, Issue 8, 2002, Pages 456-461

  Vongthavaravat, Varaphon ^a   Wajchenberg, Bernardo L ^b   Waitman, Jorge N ^c   Quimpo, Joselynna A ^d   Menon, Padmavathy S ^e   Khalifa, Fethi Ben ^f   Chow, Weng Ho ^g,h  

^a KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Argentine   (Argentina)

^d PHILIPPINE GENERAL HOSPITAL   (Philippines)

^e KEM HOSPITAL   (India)

^f LA RABTA HOSPITAL   (Tunisia)

^g Research and Development Department   (Singapore)

^h NONE   (Singapore)

Author keywords

Rosiglitazone; Sulphonylurea; Thiazolidinedione; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; APIDEX P; BANOBESE; CHLORPROPAMIDE; DEXFENFLURAMINE; FENFLURAMINE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; OBENIX; OBY CAP PHENTERMINE; PHENTERMINE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE; ZANTRYL;

ADULT; AGED; ARGENTINA; ARTICLE; BRAZIL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; HYPOGLYCEMIA; INDIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHILIPPINES; STATISTICAL SIGNIFICANCE; THAILAND; TUNISIA;

ADULT; AGED; AGED, 80 AND OVER; DEVELOPING COUNTRIES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; SULFONYLUREA COMPOUNDS; THIAZOLES; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 0036965689     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079902125001236     Document Type: Article

References (18)

1. Whitcomb RW, Saltiel AR. Thiazolidinediones. Expert Opin Investig Drugs 1995;12:1299-309
2. Patel J, Miller E, Hu J. Rosiglitazone monotherapy improves glycemic control in patients with type 2 diabetes. Diabetes, Obes Metab 1999;1:165-72
3. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001;86:280-8
4. Wolffenbuttel BHR, Gomis R, Sqautrito S, Jones NP, Patwardhan RN. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med 2000;17:40-7
5. Heine RJ. Role of sulfonylureas in non-insulin dependant diabetes mellitus: part II - 'The cons.'. Horm Metab Res 1996;28:522-6
6. Narayan KMV, Gregg EW, Fagot-Campagna A, Engelgau MM, Vinicor F. Diabetes - a common, growing, serious, costly and potentially preventable public health problem. Diabetes Res Clin Pract 2000;50(Suppl 2):S77-S84
7. Ramachandran A, Snehalatha C, Latha E, Manohara M, Vijay V. Impacts of urbanisation on the lifestyle and on the prevalence of diabetes in native Asian Indian population. Diabetes Res Clin Pract 1999;44:207-13
8. Cockram CS. Diabetes mellitus: perspective from the Asia-Pacific region. Diabetes Res Clin Pract 2000;50(Suppl 2):S3-S7
9. Mohan V, Vijayaprabha R, Rema M. Vascular complications in long-term South Indian NIDDM of over 25 years' duration. Diabetes Res Clin Pract 1996;31:133-40
10. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039-57
11. Xixing Z, Changyu P, Guangwei L, Hongli S, Hui T, Wenying Y. Rosiglitazone improves glycemic control in Chinese patients with Type 2 diabetes mellitus in combination with sulphonylureas. Diabetes 2001;50(Suppl 2):A542
12. Gomez-Perez FJ, Fanghanel-Salmon G, Barbosa JA, Montes-Villarreal J, Berry RA, Warsi G, Gould EM. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev 2002;18:127-34
13. Barnett A. Rosiglitazone in type 2 diabetes: an evaluation in British Indo-Asian patients. Diabet Med 2001;18(Suppl 2):A40
14. Nolan JJ, Jones NP, Patwardhan R, Deacon LF. Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus. Diabet Med 2000;17:287-94
15. Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001;24:1226-32
16. Betteridge DJ. Diabetic dyslipidaemia. Eur J Clin Invest 1999;29(Suppl 2):12-16
17. Turner RC, Cull CA, Frighi V. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005-12
18. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53